Juno Therapeutics, Inc. (JUNO) Given Consensus Rating of “Hold” by Brokerages

Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have been given a consensus recommendation of “Hold” by the nineteen research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $48.17.

A number of research firms have commented on JUNO. Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price objective on the stock in a research note on Tuesday, August 29th. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Raymond James Financial lifted their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 6th. Finally, Standpoint Research restated a “reduce” rating on shares of Juno Therapeutics in a research note on Thursday, August 31st.

In other news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the transaction, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders own 15.08% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Capital International Investors acquired a new position in Juno Therapeutics during the third quarter worth about $256,339,000. Redmile Group LLC acquired a new position in Juno Therapeutics during the second quarter worth about $66,344,000. Jennison Associates LLC grew its position in Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after buying an additional 1,229,622 shares during the period. Orbimed Advisors LLC grew its position in Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after buying an additional 1,126,400 shares during the period. Finally, Capital Guardian Trust Co. acquired a new position in Juno Therapeutics during the third quarter worth about $37,400,000. Institutional investors and hedge funds own 70.37% of the company’s stock.

Shares of Juno Therapeutics (JUNO) opened at $47.41 on Thursday. Juno Therapeutics has a 1 year low of $17.52 and a 1 year high of $63.45. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the company earned ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. sell-side analysts forecast that Juno Therapeutics will post -4.02 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://transcriptdaily.com/2017/12/14/juno-therapeutics-inc-juno-given-consensus-rating-of-hold-by-brokerages.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply